How to choose antibacterial drugs in the treatment of osteosarcoma

Osteosarcoma brings great pain to patients. Since this disease is more common in young people, it will have a great impact on young minds. Many children will lose their studies or even their lives. In fact, osteosarcoma can be treated in the early stages, but how to choose antibacterial drugs to treat osteosarcoma? The following is a detailed introduction.

High-dose chemotherapy combined with multiple drugs can kill local tumors. Preoperative chemotherapy (neoadjuvant chemotherapy) can cause tumor cell necrosis, tumor shrinkage, disappearance of edema in the reaction area and new tumor blood vessels, and clearer tumor calcification boundaries. Clinically, the patient's pain is relieved or disappears, the tumor becomes smaller, the joint range of motion increases, and AKP can be reduced to normal. High-dose chemotherapy is also an effective method for systemic treatment of osteosarcoma. Chemotherapy can kill micro-metastases in the lungs and throughout the body. This treatment should be performed early. Micro-lesions are more sensitive to chemotherapy than large tumors. Adjuvant chemotherapy can reduce the number of tumors in the lungs and delay their appearance. The key to prolonging the survival of patients with lung metastasis is to completely remove the metastasis. Chemotherapy can promote the radical cure of the entire disease and increase the cure rate. Twenty to forty percent of patients abroad can be cured through multiple treatments.

If neoadjuvant chemotherapy cannot achieve tumor necrosis, delaying surgical treatment will affect the survival rate. Because when chemotherapy is ineffective, the tumor will continue to reproduce and microscopic lesions in the lungs will develop. When chemotherapy is effective, delaying radical surgery for the tumor will not jeopardize the survival rate. Preoperative chemotherapy can increase the success rate of limb salvage, so preoperative chemotherapy is safe and beneficial for patients preparing for limb salvage. The effect of preoperative chemotherapy can predict the cure rate. The successful implementation of chemotherapy has enabled osteosarcoma patients to not only improve their survival rate, but also retain their limbs and have a certain degree of joint function.

From 1982 to 1988, many foreign authors used preoperative and postoperative chemotherapy to treat osteosarcoma using cisplatin (DDP), doxorubicin (ADR), methotrexate-tetrahydrofolate (MTX-CF), BCD, ifosfamide (IFO), cyclophosphamide (CTX), etc., and the metastasis-free survival rate was 42%.